Amylyx Pharmaceuticals, Inc. stock soars to $35.11, but $350M offering clouds outlook
Covered by 1 source · 1 article
Amylyx Pharmaceuticals, Inc. stock surged to $35.11 on August 18 after its Phase 3 LUCIDITY trial for avexitide met all endpoints in post-bariatric hypoglycemia. Volume exceeded 23.6 million shares on the stock’s best day in nearly four yea…
Covered by
